Compare Merck & Co., Inc. (MRK) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs S&P Global Inc — how do they compare? Merck & Co., Inc. trades at $148.24 (market cap $366.28B), while S&P Global Inc trades at $419.2 (market cap $126.56B). The key difference: Merck & Co., Inc. is far larger — about 2.9× S&P Global Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | SPGI | |
|---|---|---|
Market Cap | $366.28B | $126.56B |
Sector | Health | Financials |
52-Week High | $156.43 | $522.21 |
52-Week Low | $77.60 | $370.42 |
Enterprise Value | $413.04B | $138.05B |
Dividend Yield | 2.29% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SPGI trades at $429.31, down 3.2% over 24h, with a bullish technical signal and strong fundamentals including a 30.54% net income margin and consistent earnings beats. Recent news highlights strategic acquisitions and a focus on AI-resistant businesses, while analyst consensus remains strongly positive with an 85.7% buy rating.
Outlook is favorable due to high profitability and growth initiatives, but risks include rising debt levels and market sensitivity. The stock offers upside to the $523.20 consensus target, supported by institutional interest and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
